1k citations
- Roche (Switzerland)CH5 papers
- Novartis (Switzerland)CH4 papers
- Science Wares (United States)US4 papers
- University of TorontoCA4 papers
- Bayer (Germany)DE3 papers
- Google (United States)US3 papers
- Imperial College LondonGB3 papers
- Pacific Northwest National LaboratoryUS3 papers
- AstraZeneca (United Kingdom)GB2 papers
- Boehringer Ingelheim (China)CN2 papers
- Boehringer Ingelheim (Egypt)EG2 papers
- Bristol-Myers Squibb (Germany)DE2 papers
Showing 2020 · stat.APShow all
3 papers · 2 filters
stat.AP2020★ 28 cited
Survival analysis for AdVerse events with VarYing follow-up times (SAVVY) -- estimation of adverse event risks
Regina Stegherr, Claudia Schmoor, Jan Beyersmann +12
The SAVVY project aims to improve the analyses of adverse event (AE) data in clinical trials through the use of survival techniques appropriately dealing with varying follow-up tim…
stat.AP2020★ 4 cited
Survival analysis for AdVerse events with VarYing follow-up times (SAVVY) -- comparison of adverse event risks in randomized controlled trials
Kaspar Rufibach, Regina Stegherr, Claudia Schmoor +12
Analyses of adverse events (AEs) are an important aspect of the evaluation of experimental therapies. The SAVVY (Survival analysis for AdVerse events with Varying follow-up times)…
stat.AP2020★ 1 cited
Heterogeneity Learning for SIRS model: an Application to the COVID-19
Guanyu Hu, Junxian Geng
We propose a Bayesian Heterogeneity Learning approach for Susceptible-Infected-Removal-Susceptible (SIRS) model that allows underlying clustering patterns for transmission rate, re…